Clinical trials
Gastric clinical trials
Below are recruiting gastric clinical trials, each written for real people, not researchers. We’re tracking 860 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06085755RecruitingPhase 1/Phase 2
Combination drug therapy for HER2-low stomach cancer
This trial tests two targeted drugs, trastuzumab deruxtecan and afatinib, together for advanced stomach or gastroesophageal junction cancer that has low levels of the HER2 protein. The goal is to see if the combination shrinks tumors or slows cancer growth.
SeoulAges 19 years+ - NCT06098742Recruiting
Comparing a new liquid antacid to chewable Riopan in healthy adults
This trial tests whether a new liquid antacid (Antareit) works as well as the chewable Riopan tablets in healthy people. It involves a small tube placed through your nose to measure stomach acid before and after taking the medication.
MoscowAges 18–45 - NCT06113861Recruiting
Better TB testing for kids in Bolivia
This trial tests new ways to diagnose tuberculosis (TB) in children with breathing problems. It aims to make TB detection faster and more accurate for kids who might have the infection.
Santa CruzAges 2 months–14 years - NCT06123338RecruitingPhase 2
Pembrolizumab plus chemo and trastuzumab for HER2+ stomach cancer
This trial tests adding pembrolizumab to standard trastuzumab and chemotherapy for people with HER2-positive stomach or esophageal cancer that can be fully removed with surgery. The goal is to see if this combination improves outcomes before and after surgery.
Boston, MassachusettsAges 18 years+ - NCT06126406RecruitingPhase 1
CEA-targeting CAR-T cell therapy for advanced solid tumors
This trial tests a new immune cell therapy (CAR-T) designed to attack cancer cells that make a protein called CEA. It may be an option for people with advanced colorectal, esophageal, gastric, or pancreatic cancer who have already tried at least two standard treatments.
Wuhu, AnhuiAges 18 years+ - NCT06157996RecruitingPhase 2
Lenvatinib, Tislelizumab, and CapeOX for advanced stomach cancer
This trial tests a combination of three drugs (lenvatinib, tislelizumab, and CapeOX chemotherapy) as the first treatment for advanced stomach or gastroesophageal junction cancer that is PD-L1 positive and has a low TMEscore. The goal is to see if this combination helps control the cancer better than standard treatments.
Guangzhou, GuangdongAges 18 years+ - NCT06158919Recruiting
Immunotherapy Plus Targeted Therapy and Chemo for Stomach Cancer
This trial tests a combination of immunotherapy (PD-1 inhibitor), a targeted drug (fruquintinib), and chemotherapy as a first treatment for advanced stomach or gastroesophageal junction cancer that is HER2-negative. It aims to see if this combination can shrink tumors and help people live longer.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06186089Recruiting
How stomach surgery affects gut bacteria and your thinking
This study looks at how having stomach cancer surgery changes your gut bacteria and thinking abilities. Researchers want to understand if these changes affect memory or brain function after the operation.
Wuhan, HubeiAges 40–80 - NCT06199895RecruitingPhase 2
Study of paclitaxel for patients with taxane-resistant solid tumors
This trial tests paclitaxel given as tiny micelle particles for people whose cancer (pancreatic, bile duct, lung, stomach, esophagus, or breast) stopped responding to taxane chemotherapy or did not shrink. The goal is to see if this treatment can help when standard taxanes no longer work.
Wuhan, HubeiAges 18 years+ - NCT06203327Recruiting
Can atrophic gastritis predict stomach cancer risk?
This trial studies whether a condition called atrophic gastritis (thinning of the stomach lining) can help predict who is more likely to develop stomach cancer. It may help with early detection and prevention.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06222645Recruiting
Comparing two dyes in gastrointestinal surgery
This trial compares two dyes used during stomach or intestine surgery to see which helps surgeons see the blood flow better. It may help decide which dye works best for safe reconnections.
Yantai, ShandongAges 18 years+ - NCT06227728Recruiting
Predicting immunotherapy response in advanced cancer
This study uses blood and tumor samples to find markers that predict whether immunotherapy will work for people with stage IV cancer. The goal is to better match treatments to patients.
Ho Chi Minh City, Hồ Chí MinhAges 18–80 - NCT06239194RecruitingPhase 1/Phase 2
MdX2001 for advanced solid tumors
This trial tests a new drug, MDX2001, for people with advanced solid tumors that have spread. The study aims to find the best dose and see how well it works.
Denver, ColoradoAges 18 years+ - NCT06242470RecruitingPhase 1
Study of MGC026 for advanced solid tumors
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
Los Angeles, CaliforniaAges 18 years+ - NCT06253871RecruitingPhase 1
Study of IAM1363 for HER2 Cancers
This trial tests a new oral drug called IAM1363 for people with HER2-altered cancers that have stopped responding to previous treatments. The goal is to see if the drug is safe and how well it works against these cancers.
La Jolla, CaliforniaAges 18 years+ - NCT06266299RecruitingPhase 1
Study of KK2269 for adults with solid tumors
This trial tests a new drug called KK2269 for adults with solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective, possibly as a treatment option for certain cancers like lung or stomach cancer.
Scottsdale, ArizonaAges 18 years+ - NCT06275204Recruiting
H. pylori test and treat study for young adults
This study tests and treats young adults for H. pylori, a stomach bacteria, to see if treating it reduces future health risks. If you haven't been treated for H. pylori before, you may join.
Zagreb, City of ZagrebAges 30–34 - NCT06277024Recruiting
Combination therapy for advanced HER2-negative stomach cancer
This trial tests a combination of immunotherapy (candenizumab), a targeted therapy (lenvatinib), and chemotherapy (SOX regimen) for advanced HER2-negative stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if this combination is safe and works better than standard treatments.
Fuzhou, FujianAges 18–75 - NCT06293703Recruiting
Leg length ratio and weight loss after gastric bypass
This study looks at how the length of different parts of your small intestine affects weight loss after Roux-en-Y gastric bypass surgery. It may help doctors tailor the surgery for better results.
Cleveland, OhioAges 18–70 - NCT06298916RecruitingPhase 1/Phase 2
Study of 64Cu-LNTH-1363S in Sarcoma or GI Cancer
This trial tests a new imaging agent, 64Cu-LNTH-1363S, to see if it can find certain sarcomas and gastrointestinal cancers. The goal is to help doctors better see where your cancer is and plan the best treatment. You may be eligible if you have a sarcoma or a GI cancer and are willing to have a tumor tissue sample taken.
Duarte, CaliforniaAges 15 years+ - NCT06300879Recruiting
New surgery technique for upper stomach or junction cancer
This study tests a new surgical technique for removing cancer in the upper stomach or where the stomach meets the esophagus. It aims to see if this technique is safe and effective for people with early-stage adenocarcinoma who haven't had other cancer treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06313801RecruitingPhase 2
Chemotherapy with or without PIPAC for stomach cancer
This trial tests whether adding a special type of chemotherapy sprayed directly into the abdomen (PIPAC) to standard chemotherapy is safer and works better for stomach cancer that has spread only to the lining of the abdomen.
Nizhny NovgorodAges 18–75 - NCT07341737RecruitingPhase 1/Phase 2
SL-28 for advanced solid tumors that haven’t responded to treatment
This trial tests a new drug, SL-28, for people with advanced solid tumors that haven’t responded to or cannot be treated with standard therapies. It aims to find a safe dose and see if the drug can help shrink or slow the growth of your cancer.
Adelaide, South AustraliaAges 18 years+ - NCT07624383Recruiting
New topical treatment for nonerosive acid reflux disease
This study tests a new topical treatment for people with chronic heartburn and acid regurgitation who don't have erosions (damage) in their esophagus. The treatment is applied directly to the affected area and may help relieve symptoms without taking daily pills.
Warsaw, Masovian VoivodeshipAges 18 years+
Hear when a new Gastric trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gastric?
- Yes. Clin2 currently lists 860 recruiting gastric studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gastric trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gastric trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.